Test Price
2,800 AED✅ Home Collection Available
JAM3 Gene Hemorrhagic Brain Destruction, Subependymal Calcification & Cataracts Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
- 99.9% Diagnostic Sensitivity – ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) NGS processing.
- VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – Available daily 8 AM to 11 PM.
- Telephonic Post-Test Clinical Guidance – DHA-licensed genetics specialist provides result interpretation.
- Insurance Direct Billing – Verify coverage via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The JAM3 gene test detects pathogenic variants responsible for a severe autosomal recessive syndrome featuring hemorrhagic brain destruction, subependymal calcification, and congenital cataracts. This next‑generation sequencing (NGS) assay provides comprehensive coverage of the coding regions, splice sites, and copy number variants, delivering actionable genetic information for families and clinicians.
| Feature | Our Test (JAM3 NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | >99.9% sensitivity for SNVs, indels & CNVs | Limited to known hotspots; misses large rearrangements |
| Method | NGS with bioinformatics per ACMG guidelines, CNV calling | Sanger dideoxy chemistry, manual analysis |
| Turnaround | 3 – 4 weeks | 6 – 8 weeks |
Physician Insight & Safety Protocols
“In my practice, families affected by unexplained neonatal brain hemorrhage and early cataracts often face a long diagnostic journey. This JAM3 genetic test provides definitive answers with remarkable accuracy, enabling targeted surveillance, early intervention, and informed family planning. However, a genetic result must always be interpreted alongside clinical and imaging findings — it is a critical piece of the diagnostic puzzle, not a standalone answer.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Do not discontinue or alter prescribed medication without consulting your doctor. This genetic test does not replace ongoing clinical care or treatment plans.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Active infection at venipuncture site; uncontrolled coagulopathy (assess with physician prior to blood draw).
- Exclusion: Inability to provide informed consent – for minors, legal guardian consent is mandatory as per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Emergency Red Flags: If the patient experiences sudden severe headache, loss of consciousness, seizures, or acute vision loss, seek immediate emergency care – do not wait for test results.
Patient FAQ & Clinical Guidance
1. What is the JAM3 gene test and when is it recommended?
This high‑depth NGS assay analyzes the entire JAM3 gene to identify pathogenic variants linked to a severe syndrome of brain hemorrhagic destruction, subependymal calcification, and congenital cataracts. It is recommended for infants or children presenting with unexplained neonatal brain hemorrhage, intracranial calcifications, or congenital cataracts, as well as for families with a history of the condition for carrier testing or prenatal diagnosis.
2. How is the sample collected and what is the experience like?
A sample of 3–5 mL of whole blood or a simple finger‑prick FTA card is collected by a DHA‑licensed phlebotomist using a cold‑chain kit. The procedure is minimally uncomfortable and typically completed in under five minutes. Our VIP mobile phlebotomy service is available daily from 8 AM to 11 PM for home collection.
3. How accurate are the results and how long does it take to receive them?
Our ISO‑certified NGS platform achieves 99.9% diagnostic sensitivity for single nucleotide variants, indels, and copy number variants. The final clinical report is delivered within 3–4 weeks and includes variant interpretation per current ACMG guidelines, along with complimentary telephonic guidance from our genetics consultant.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates in full compliance with the UAE's regulatory framework for healthcare and data protection:
- Data Privacy: All patient data processed in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Health Information Security: Adherence to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Medical Liability: Testing and consent procedures follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
- DHA License: DHA Facility License Number 1143, Dubai Healthcare City.
Your genetic data is encrypted, anonymized, and never shared with third parties without explicit consent.
Clinical & Logistical Metadata
| Test Name | JAM3 Hemorrhagic Brain Destruction, Subependymal Calcification & Cataracts Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole Blood (3-5 mL) or FTA Card (Dried Blood Spot) |
| Methodology Used | Next-Generation Sequencing (NGS) with CNV detection |
| ICD-10-CM Code | Q04.8, Q12.0 |
| LOINC Code | 21636-8 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians